Findings from an exploratory analysis from the INDIGO study evaluating the impact of VORANIGO on seizure rates and quality of life will be shared in a separate poster presentation BOSTON, May 31, 2026 ...
BOSTON, May 31, 2026 /PRNewswire/ -- Servier today announced updated efficacy and safety results from more than three years of follow-up in the Phase 3 INDIGO trial evaluating VORANIGO® (vorasidenib) ...
Latest long-term analysis, including more than three years of follow-up data of patients with Grade 2 IDH-mutant glioma treated with VORANIGO ® (vorasidenib), will be presented in a rapid oral session ...
The extended analysis includes 21.3 months of additional unblinded data collected between the March 7, 2023, trial unblinding and the January 17, 2025, data cutoff. As of data cutoff, all 163 patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results